Organization | AP Moeller Foundation

AP Moeller Foundation Report issue

Foundation Phase 2 Phase 4

Founded: Copenhagen Denmark (1953)

Organization Overview

First Clinical Trial

2003

NCT00168558

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

AP Moeller Foundation

Active Ingredients

Drugs in Phase 4 Trials (5)

aripiprazole (abilify) (1 trial)

attenuated measles vaccine (rubeovax) (1 trial)

epinephrine (levophed) (3 trials)

lidocaine (xylocaine) (3 trials)

quetiapine (seroquel) (1 trial)

Drugs in Phase 2 Trials (2)

gadoteric acid (Dotarem) (2 trials)

progesterone (progestasert) (1 trial)

Drugs in Other Trials (4)

aflibercept (zaltrap) (1 trial)

insect protein (1 trial)

pea protein (1 trial)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hip Fractures (Phase 4)

Measles (Phase 4)

Mental Disorders (Phase 4)

Pain, Postoperative (Phase 4)

Premature Birth (Phase 2)

Psychotic Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 8
# of Trial APIs: 11